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Background: Flavonoids are structurally heterogeneous, polyphenolic compounds present in high concentrations
in fruits, vegetables, and other plant-derived foods. Currently, there is growing interest in the therapeutic applications of
bioflavonoids for the treatment and prevention of diseases in humans. Myricetin is a naturally occurring flavonoid that
is commonly found in tea, berries, fruits, vegetables, and medicinal herbs. Previous studies have shown that myricetin
has antioxidant, anti-inflammatory and potent anticancer effects. It was interesting to investigate whether myricetin has
the cooperative inhibitory effect combined with 5-fluorouracil on esophageal cancer cells.
Methods: EC9706 cells were treated with 5-fluorouracil combination with or without myricetin. Colony formation
assays, CCK-8 assay and flow cytometry were used to evaluate the chemosensitization activity of myricetin combine
with 5-fluorouracil on the cell growth and viability, cell proliferation and apoptosis in vitro. Western blot was engaged
to detect changes of Survivin, Cyclin D, Bcl-2, Caspase-3 and P53 protein expression level, which were associated with
cells proliferation and apoptosis. Nude mouse tumor xenograft model was built to assessed chemosensitization effect
of myricetin combine with 5-fluorouracil in vivo.
Results: Compared with the 5-fluorouracil group without myricetin treatment, the groups treated with 5-fluorouracil
combine with myricetin showed significantly suppressed cell survival fraction and proliferation, increased the cell
apoptosis. Decreased Survivin, Cyclin D, Bcl-2, and increased Caspase-3, P53 expression level were aslo confirmed by
western blot in 5-fluorouracil combine with myricetin groups in vitro. And in vivo assay, growth speed of tumor
xenografts was significantly decreased in the mice treated with 5-fluorouracil + myricetin combiantion group.
Conclusions: The study demonstrated both in vitro and in vivo evidence that combination of myricetin with
5-fluorouracil chemotherapy can enhance tumor chemosensitivity of esophageal cancer EC9706 cells, and myricetin
could be a potential chemosensitizer for esophageal cancer therapy.
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Esophageal cancer is a global health problem that ranked
eighth in terms of incidence and sixth in terms of mortal-
ity [1,2]. The northern regions in Henan province of China
have the highest incidence of esophageal cancer, particu-
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unless otherwise stated.[3,4]. Generally, the primary tumor of most patients can
be cured with surgical resection, however, due to early dis-
tant metastases, the remainder of patients will eventually
succumb to the disease. Systemic chemotherapy is regarded
as one of the most effective treatments to improve survival
[5-7]. However, the toxicity of most chemotherapy agents
to normal tissues was the main obstacle to successful treat-
ment. Therefore, to enhance efficacy and reduce toxicity
become the tendency for chemotherapy regimens.
5-Fluorouracil (5-FU) was universally used as an anti-
cancer agent in esophageal carcinoma [8,9]. In order ton Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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many previous studies were engaged to find more effective
candidate mechanism to enhance 5-FU therapeutic effect
with lower toxicity for normal tissues [10-13].
Most epidemiological evidence has shown that dietary
habit and lifestyle play important roles in developing EC.
And some studies indicated that tobacco and alcohol have
roles in this cancer [14,15], however, high consumption of
vegetables and fruits could reduce the risk of EC [16,17].
Flavonoids are structurally heterogeneous, polyphenolic
compounds present in high concentrations in fruits, vege-
tables, and other plant-derived foods. Currently, there is
growing interest in the therapeutic applications of biofla-
vonoids for the treatment and prevention of diseases in
humans. Myricetin (3,3’,4’,5,5’,7- hexahydroxyflavone) is a
naturally occurring flavonoid that is commonly found in
tea, berries, fruits, vegetables, and medicinal herbs et al.
[18,19]. Previous studies have shown that myricetin has
antioxidant, anti-inflammatory and potent anticancer ef-
fects [19-21]. It was interesting to investigate whether
myricetin has the cooperative inhibitory effect combined
with 5-fluorouracil on esophageal cancer cells.
In this study, we engaged esophageal squamous carcin-
oma cell line EC9706 to observe the effects of myricetin
on combination with 5-fluorouracil enhances tumor che-
mosensitivity in vitro and in vivo, in order to provided a
novel insight into myricetin as a potential agent for
esophageal cancer chemosensitizers.
Materials and methods
Chemicals and cell culture
Myricetin and 5-FU (C4H3FN2O2) were purchased from
Sigma-Aldrich, and dissolved in dimethylsulfoxide
(DMSO) for storage at -20°C. Human esophageal squa-
mous carcinoma cell line EC9706 was purchased from
Shanghai Institutes for Biological Sciences, Chinese
Academy of Sciences. The cells were routinely cultured
in DMEM (Gibco, USA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 U/mL penicil-
lin and 100 μg/mL streptomycin in a humidified cell
incubator with an atmosphere of 5% CO2 at 37°C.
Colony-forming survival assay
The overall survival of the cells treated with myricetin
alone, 5-FU alone or in combination with different con-
centration, was assessed by the rate of colony formation.
EC9706 cell were plated into 6-well plates and exposed
to different concentration of myricetin (final concentra-
tion: 0 μM, 25 μM, 50 μM, 100 μM), After 4 hours later,
5-FU (10 μM, 20 μM, 40 μM, 80 μM, 160 μM) was
added into the culture and maintained for 48 hours.
48 hours later, all cells were then washed, trypsinized,
counted, and plated into 10 cm dishes containing DMEM
supplemented with 10% FCS until colony formation wasvisible, which usually occurred in approximately 10-14
days. The colonies formed were stained with crystal violet,
and the colonies with >50 cells scored as surviving colonies.
The plating efficiency was calculated by dividing the aver-
age number of colonies per dish by the amount of cells
plated. Survival fractions were calculated by normalization
to the plating efficiency of appropriate control groups.
In vitro cell proliferation assay
EC9706 cell lines in logarithmic phase growth were
seeded into 96-well plates at a density of 1 × 104 cells/
well with three replicate wells. After 24 h incubation,
when the cells were adhesive, the cells were exposed to a
range of concentration of myricetin (0 μM, 25 μM,
50 μM, 100 μM), After 4 hours later, 5-FU (20 μM,
40 μM, 80 μM, 160 μM, 320 μM) was added into the
culture. After exposed for 48 h, OD was measured by
WST (water-soluble tetrazolium salt) assay using micro-
plate computer software (Bio-Rad Laboratories, USA)
according to the protocol of Cell Counting Kit-8 (CCK8)
assay kit (Dojindo, Japan). 450 nm absorbance was read
on a microplate reader (168–1000 Model 680, Bio-Rad,
Hercules, USA). The curves of cell proliferation were
plotted. Triplicate parallel experiments were performed
for each concentration. The rate of inhibition was calcu-
lated by the following equation: rate of growth inhibition
(%) = (ODcontrol – ODtreated)/ODcontrol × 100%.
Cell cycle analysis
Flow cytometry (BD FACS Canto II) was used to con-
duct cell cycle analysis. EC9706 cells treated with 0.1%
DMSO (control) and different concentration of myrice-
tin (combined with or without 5-FU) for 48 hours was
trypsinized and washed twice with PBS. Then cell dens-
ity was adjusted at 1 × 109/L with 1 mL PBS and fixed in
70% cold ethanol overnight at 4°C. Adding 100 μL
RNase A (1 g/L) into the cells, and keeping at 37°C for
30 min. Before the analysis, 400 μL of 10 mg/L propi-
dium iodide (PI) was added into cells and then kept in
dark for 30 min. The percentage of the cells in each phase
of cell cycle was measured by FACScan system and the re-
sults were analyzed using CellQuest software.
Cell apoptosis assay
Annexin V-FITC/PI apoptosis detection kit (Vazyme
Biotech) was used to detect and quantify the presence of
apoptotic cells. EC9706 cell lines in logarithmic phase
growth were seeded in 6-well plate with 2.0 × 105 cells in
each well. Four groups (control group, 5-FU alone group,
myricetin alone group, and combination group) cells were
harvested and counted at 48 hours after incubated. The
cell pellets were resuspended in 195 μL of binding buffer
and stained with 5 μL each of annexin V-FITC and PI
staining solution for 10 minutes at room temperature in
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formed with the FACScan system using CellQuest soft-
ware. Cell apoptosis rate was calculated as: (the number of
cell apoptosis in each group/the total number of cells in
each group) × 100%.
Western blot analysis
Cell harvest was same as the method of cell apoptosis
assay. Total protein was extracted from each group cells
using RIPA buffer containing PMSF. A BCA protein assay
kit (Beyotime, Haimen, China) was used to determine total
protein concentration. Protein samples were resolved by
electrophoresis of SDS-PAGE gels and transferred onto
PVDF membranes. After blocking, the membranes were
incubated overnight at 4°C with diluted primary antibody
(the following antibodies were used: Survivin, Cyclin D1,
Bcl-2, Caspase-3 and P53, 1:1000, Santa Cruz Biotechnol-
ogy) and followed by incubation with an HRP-conjugated
secondary antibody (1:1000, Santa Cruz Biotechnology).
An antibody against GAPDH (Santa Cruz Biotechnol-
ogy) served as an endogenous reference. Protein inten-
sity were scanned on Typhoon PhosphorImager (GE
Healthcare) for fluorescent signal. Experiments were
performed in triplicate.
Human tumor xenograft model in nude mouse
Immunodeficient female BALB/C nude mice, 5-6 weeks
old, were from the Experimental Animal Center of
Henan province, China. The mice were subcutaneously
injected in the dorsal scapular region with EC9706 cells.
In addition, a sufficient number of mice were implanted
in order that tumors in a weight range as narrow as pos-
sible were selected for the trial on the day of treatment
initiation (1 week after tumor cells implantation). The
tumors were allowed to reach about 75-100 mm3 in size
before the start of treatment. Then the mice were di-
vided into four groups: myricetin group (25 mg/kg), 5-
FU group (20 mg/kg), combination group, and saline
control group. The mice were treated with chemother-
apy using 3-week cycle regimen (×3 cycles) as previously
described [22]. The tumor volume is measured with a
caliper every 5 days, and tumor volume was calculated
using the formula: volume = π (length × width2)/6. This
study was complied with the NIH Guide for the Care
and Use of Laboratory Animals. The protocol was ap-
proved by the committee on the Ethics of Animal Ex-
periments of Zhengzhou University. All surgery was
performed under sodium pentobarbital anesthesia, and
all efforts were made to minimize suffering.
Statistical analysis
SPSS 13.0 was used for statistical analysis. One-way ana-
lysis of variance (ANOVA) was used to analyze the sig-
nificance between groups. Multiple comparisons weremade using the Least Significant Difference test when
the probability for ANOVA was statistically significant.
All data represent mean ± SD. Statistical significance was
set at P < 0.05.Results
Myricetin increased chemosensitivity of 5-FU on tumor
cells in vitro
To determine the effects of myricetin on tumor cells che-
mosensitivity, a clonogenic survival analysis was per-
formed. It was found that treatment of the EC9706 cells
with different concentration 5-FU alone could lead to in-
hibition effect on clonogenic survival. However, when
combined with different concentration of myricetin, the
surviving fraction decreased significantly (Figure 1).Myricetin enhances chemosensitivity on inhibiting the
EC9706 cells proliferation
CCK-8 assay was used to measure the effect of chemosen-
sitization activity of myricetin on the growth and viability
of EC9706 cells in vitro. Compared to the control (no
myricetin and no 5-FU), the proliferation of EC9706 cells
(Figure 2) was inhibited significantly in different consen-
tration 5-FU group. It was also found that myricetin-only
had but only limited inhibitory effect on tumor cells prolif-
eration. However, a significant increase in tumor growth
inhibition occurred for the cells treated with 5-FU combi-
nated with myricetin. The result demonstrated that myri-
cetin enhanced the chemosensitivity of EC9706 cells and
has the function as a tumor chemosensitizer in esophageal
squamous carcinoma cells in vitro.Myricetin combination with 5-FU enhances cell cycle
arrest at the G0/G1 phase
In order to examine whether the chemosensitivity of myri-
cetin was related to cell cycle arrest, we next measured the
cell cycle in EC9706 cells with flow cytometry analysis and
PI staining. The phases distribution of cell cycle indicated
that both 5-FU and myricetin could increase the percent-
age of EC9706 cells in G0/G1 phase and prevent cells enter-
ing into the S phase. As shown in Figure 3, EC9706 cells
treated with myricetin or 5-FU resulted in a statistically
significant increase in the G0/G1 phase that was accompan-
ied by a decrease in the S phase. Furthermore when 5-FU
combination with myricetin, the G0/G1 phase percentage
increased significantly to 85.9%, compared with 5-FU alone
(68.8%) or myricetin alone (62.1%). These results indicate
that myricetin could enhance 5-FU chemosensitivity on
cell cycle arresting in the G0/G1 phase, and delay the pro-
gression of the cell cycle, and inhibits proliferation of
EC9706 cells.
Figure 1 Myricetin enhance chemosensitivity of 5-FU on cancer
cells in vitro. Cells were treated with indicated doses of myricetin
and 5-FU for 48 h and colony formation assays were conducted.
Chemosensitivity was measured by colony formation assay in the
esophageal squamous carcinoma cell line EC9706. Compared to the
control (0 μM myricetin), clonogenic survival of EC9706 cells treated
with myricetin were decreased significantly under different 5-FU
doses. Shown are averages of triplicate samples. Standard errors are
shown by error bars.
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cells apoptosis
To investigate the apoptosis effect of myricetin-induced
chemosensitization, we used flow cytometry (FCS) to
measure the effect of myricetin and 5-FU on apoptosis in
EC9706 cells. The cell stained with Annexin V-positive,
PI-positive or both positive were defined to apoptosis cells.
As shown in Figure 4. Compared to the control, both the
apoptosis rate of EC9706 cells were increased in myricetin-Figure 2 Myricetin enhances 5-FU chemosensitivity on inhibiting
the esophageal tumor cell proliferation. Chemosensitivity was
measured by CCK-8 assay in EC9706 cells treated with different
concentration myricetin combine or not combine with 5-FU.
Compared to the control group (0 μM myricetin), the proliferation
inhibition rate of EC9706 cells were increased significantly in 5-FU
chemotherapy combine with myricetin group.alone group and 5-FU-alone group (P < 0.05). And further-
more, the apoptosis rate was significantly enhanced in 5-FU
and myricetin combination group. Meanwhile, compared
with the 5-FU alone group, the the apoptosis effect was ob-
viously enhanced in 5-FU+myricetin combination group
(P < 0.05).
Myricetin enhances the 5-FU effection on alteration of the
genes expression
After establishing myricetin enhanced 5-FU chemosensi-
tivity to cell cycle arrest at G0/G1 and induced apoptosis,
we sought to investigate the underlying molecular mech-
anism. To examine whether myricetin in combination
with 5-FU promotes the chemosensitivty of 5-FU in
EC9706 cells by regulating the expression of Survivin,
Cyclin D1, Bcl-2, Caspase-3 and P53 protein, we engaged
western-blot to checked these protein expression levels
(Figure 5). Compared to the control, the expression levels
of Survivin, Cyclin D1 and Bcl-2 in both myricetin and 5-
FU group were decreased, while the Caspase-3 and P53
level was increased (P < 0.05). Furthermore, more alter-
ation changes of these protein expression level were ob-
served in myricetin and 5-FU combination group. The
expression level of Survivin, Cyclin D1 and Bcl-2 in myri-
cetin and 5-FU combination group were more lower than
in myricetin alone or 5-FU alone group (P < 0.05), while
more higher expression level of Caspase-3 and P53 in
combination group than in myricetin alone or 5-FU alone
group (P < 0.05). These clear results explained that myrice-
tin in combination with 5-FU could promote the chemo-
sensitivity of 5-FU in EC9706 cells by regulating the
expression of Survivin, Cyclin D1, Bcl-2, Caspase-3 and
P53, when compared with 5-FU treatment.
The chemosensitizing effect of myricetin in vivo
Because myricetin has the chemosensitization activity on
cell survival, proliferation and apoptosis in vitro, we per-
formed a proof-of-principle experiment using a esophageal
cancer EC9706 cell xenograft mice model to determine
chemosensitizing effect of myricetin in vivo. We found that
myricetin-alone group had less inhibitory effect on tumor
growth, compared with tumors treated with 5-FU alone
(Figure 6). However, a significant slower down in tumor
growth occurred for mice treated with 5-FU combination
with myricetin. These results demonstrated that myricetin
could increase esophageal tumor cell killed by 5-FU in vivo,
and further indicated that myricetin can function as a
powerful chemosensitizer for esophageal cancer.
Discussion
Esophageal carcinoma is one of the most aggressive ma-
lignancies and has become an emerging public health
problem for its high morbidity and mortality [23,24].
More effective treatments, as well as methods for earlier
Figure 3 Myricetin enhances 5-FU chemosensitivity on interrupting progression of cell cycle. Cell cycle distribution was analyzed by flow
cytometry. Data are presented as the mean of triplicate experiments. EC9706 cells incubated with 5-FU (80 μM) or myricetin (50 μM) showed
increased G0/G1 phase percentage significantly, and decreased the S and G2/M phase fractions. And when 5-FU combination with myricetin, the
effect of interrupting progression of cell cycle become more obvious (*P < 0.05 vs control, # P < 0.05 vs 5-FU group).
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cades. However, patients with esophageal cancer still ex-
hibit rapid progression and poor prognosis, owing to
extensive local invasion, lymph node involvement and
distant metastases at the time of diagnosis [25,26]. Con-
sequently, more effective chemotherapies have become
an important means of extending the survival of esopha-
geal cancer patients. 5-FU, a pyrimidine analogue of
road-spectrum anticancer drug, is widely used in chemo-
therapeutic regimens [27], but the large side effects
which it has been shown are a still limit aspect for use.
The development of novel strategies for inhibiting tumorFigure 4 Chemosensitizing effect of myricetin on tumor cells apoptos
EC9706 cells. The cells were stained by annexin V-FITC/PI, and cell apoptosis wa
significant increased in 5-FU +myricetin combination group, compared to othecells growth and enhancing chemosensitivity are the
focus of much medical research.
Over the last few years, interest in exploring the use
of traditional medicines for the prevention or treatment
of tumors has increased. Myricetin is a naturally occur-
ring flavonol and commonly ingested through our diet
in many natural foods and medicinal herbs. There are
studies showed that myricetin has the function to in-
hibit cellular proliferation and to induce apoptosis in
tumor cells [28,29]. Acquired data have indicated the
biological activities of myricetin, such as anti-oxidant, -
inflammatory, -carcinogen, -viral, and apoptosis induction,is. Myricetin increase the chemosensitivity of 5-FU on apoptosis rate in
s analyzed by FCM. The data showed that apoptotic cells was statistically
r three groups. (*P< 0.05 vs control, # P< 0.05 vs 5-FU group).
Figure 5 Myricetin enhances the 5-FU effection on alteration of the genes expression. EC9706 cells seeded in six-well plates were treated
with myricetin (50 μM), 5-FU (80 μM) and myricetin +5-FU combination. After 48 h, total protein was extracted for western-blot. The relative
expression level of Survivin, Cyclin D, Bcl-2, Caspas-3 and P53 from each independent experiments are shown. More alteration changes of these
protein expression level were observed in myricetin and 5-FU combination group. Which indictated that myricetin in combination with 5-FU
could promote the chemosensitivity of 5-FU in EC9706 cells by regulating the expression of Survivin, Cyclin D and Bcl-2, Caspase-3 and P53
(*P < 0.05 vs control, # P < 0.05 vs 5-FU). Data are presented as the mean of triplicate experiments.
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was reasonable to hypothesize that myricetin might func-
tion as a chemosensitizer.
To test this hypothesis, we firstly conducted colony for-
mation assays and prolifetation assay in esophageal cancer
cell line (EC9706), It was found that treatment of the cells
with 5-FU chemotherapy combined with myricetin could
significantly decrease the survival fractions and prolifeta-
tion of cancer cells. And myricetin exhibited obvious effect
of enhancing chemosensitivity with 5-FU on the EC9706
cell survival and prolifetation. In addition, the growth and
proliferation of cancer cells are mediated via cell cycle
progression [30]. The inhibition of the cell cycle has be-
come an appreciated target for management of cancer
[31]. In this study, we also examine the chemosensitivity
of myricetin and 5-FU on cell cycle. Which indicated thatFigure 6 EC9706 cell xenograft tumor for detecting myricetin sensitiz
subcutaneously in immunodeficient female BALB/C nude mice. Mice treate
A. The xenograft tumors from nude mice in each groups after 2 months im
function of time after implantation. The data curve showed that 5-FU com
compared with other three groups.myricetin could enhance the 5-FU inhibition effect on the
proliferation of cancer cells by arresting the G0/G1 phase.
Meanwhile, Previous studies had established that Cyclin
D1 plays a crucial role in the progression of cell cycle from
G1 to S phase and the down-regulation of Cyclin D1
would lead to cell cycle arrest at G1 [32]. In present study,
we found that Cyclin D1 were downregulated in myricetin
and 5-FU combination treated group, and Cyclin D1 ex-
pression level was lower than in myricetin alone and 5-FU
alone groups. These results indicate that myricetin could
enhance 5-FU chemosensitivity on cell cycle arresting, and
delay the progression of the cell cycle, and inhibits prolif-
eration of EC9706 cells.
On the other hand, Apoptosis was thought to be the
major reason of cell death induced by chemosensitizer. It
is now widely recognized that drug-induced apoptosising tumors to 5-FU treatment in vivo. EC9706 cells were implanted
d with myricetin alone, 5-FU alone, and myricetin + 5-FU combination.
plantation. B. Shown are medium tumor weights of each group as
bination with myricetin could inhibit the tumor growth significantly,
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with an increased rate of apoptosis meaning that the cells
have a higher sensitivity to chemotherapy [33,34]. We ex-
amined the apoptotic effect induced by myricetin com-
bined with 5-FU or administered individually. The results
indicated that myricetin and 5-FU alone significantly in-
duced apoptosis compared with the control, and that the
combined treatment effects were stronger than the indi-
vidual effects of myricetin and 5-FU. And to further test
the chemosensitizing mechanism of myricetin on tumor
cells apoptosis, we detected the expression level of
Survivin, Bcl-2, Caspase-3 and P53, which play very im-
portant role during cells apoptosis [35-40]. The data
showed that 5-FU combine with myricetin could be more
efficient to decrease Survivin, Bcl-2 expression, and in-
crease the Caspase-3, P53 expression, which aslo indicated
that myricetin could enhanced the 5-FU chemosensitivity
of apoptosis.
And in this study, we also engaged esophageal tumor
bearing nude mice model to observe the chemosensitiz-
ing effect of myricetin in vivo. The result showed the
tumor growth speed was significantly slower down in
occurred for mice treated by 5-FU combine with myri-
cetin. These data above demonstrate that myricetin has
a chemosensitization potential in vitro and in vivo, and
further indicated that myricetin can function as a
powerful chemosensitizer for esophageal cancer treat-
ment by 5-FU.
In conclusion, the results of the current study dem-
onstrate the effect of myricetin on combination with 5-
FU enhances esophageal tumor chemosensitivity
in vitro and in vivo, it could provided a novel insight
into myricetin as a safe and potential agent for esopha-
geal carcinoma chemosensitizers to enhance the effect-
iveness of chemotherapy.
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